1. Home
  2. HURA vs REKR Comparison

HURA vs REKR Comparison

Compare HURA & REKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • REKR
  • Stock Information
  • Founded
  • HURA 2009
  • REKR 2017
  • Country
  • HURA United States
  • REKR United States
  • Employees
  • HURA N/A
  • REKR N/A
  • Industry
  • HURA
  • REKR Telecommunications Equipment
  • Sector
  • HURA
  • REKR Telecommunications
  • Exchange
  • HURA Nasdaq
  • REKR Nasdaq
  • Market Cap
  • HURA 171.7M
  • REKR 141.7M
  • IPO Year
  • HURA N/A
  • REKR N/A
  • Fundamental
  • Price
  • HURA $2.72
  • REKR $1.35
  • Analyst Decision
  • HURA Strong Buy
  • REKR
  • Analyst Count
  • HURA 2
  • REKR 0
  • Target Price
  • HURA $11.50
  • REKR N/A
  • AVG Volume (30 Days)
  • HURA 132.5K
  • REKR 6.7M
  • Earning Date
  • HURA 06-17-2025
  • REKR 05-14-2025
  • Dividend Yield
  • HURA N/A
  • REKR N/A
  • EPS Growth
  • HURA N/A
  • REKR N/A
  • EPS
  • HURA N/A
  • REKR N/A
  • Revenue
  • HURA N/A
  • REKR $45,448,000.00
  • Revenue This Year
  • HURA N/A
  • REKR $8.68
  • Revenue Next Year
  • HURA $69.15
  • REKR $21.45
  • P/E Ratio
  • HURA N/A
  • REKR N/A
  • Revenue Growth
  • HURA N/A
  • REKR 17.97
  • 52 Week Low
  • HURA $1.80
  • REKR $0.62
  • 52 Week High
  • HURA $13.13
  • REKR $2.67
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • REKR 58.33
  • Support Level
  • HURA N/A
  • REKR $1.08
  • Resistance Level
  • HURA N/A
  • REKR $1.64
  • Average True Range (ATR)
  • HURA 0.00
  • REKR 0.15
  • MACD
  • HURA 0.00
  • REKR 0.03
  • Stochastic Oscillator
  • HURA 0.00
  • REKR 52.70

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About REKR Rekor Systems Inc.

Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which a majority of its revenue comes from the United States.

Share on Social Networks: